Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

March 26, 2024

https://www.globenewswire.com/news-release/2024/03/26/2852366/0/en/Inozyme-Pharma-to-Report-Topline-Data-from-Ongoing-Phase-1-2-Trials-of-INZ-701-in-Adults-with-ABCC6-Deficiency-and-ENPP1-Deficiency-on-April-8-2024.html

– Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET –

BOSTON, March 26, 2024 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq:INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call and webcast on Monday, April 8, 2024 at 8:00 a.m. Eastern Time.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.